The United Kingdom and the United States have forged a landmark bilateral deal that will preserve zero duties on UK pharmaceutical exports entering the US market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has committed to boost funding on pharmaceuticals through the NHS. This commitment ensures that duties on these vital goods will remain at zero for a duration of three years.
This deal is in response to recent threats to significantly raise import taxes on patented drug imports, with figures floated as high as double the cost.
"This deal with the United Kingdom strengthens the worldwide climate for cutting-edge drugs and establishes long-overdue equity to transatlantic drug exports," a statement noted.
Economic Impact
Pharmaceuticals are one of the UK's largest exports to the United States, which is by far the largest market for leading UK drugmakers.
Export figures indicate that in the year to the end of last September, the UK exported pharmaceutical products valued at over eleven billion pounds to the US. This figure accounted for 17.4% of all goods exports in that span.
"This agreement secures jobs, increases funding and sets the stage for the UK to become a global hub for life sciences," the Business and Trade Secretary stated.
Detailed UK Commitments
The agreement entails several key changes from the British government:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it deems new therapies to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a goal to raise overall NHS spending on medicines from 0.3 percent of GDP to 0.6% over the next decade.
- Refund Ceiling: The amount pharmaceutical firms must return to the NHS to prevent overspending will be restricted at fifteen percent. In the past, rebates topped twenty percent.
Recent Tensions
The pact follows a long-running tension between the drug companies and the ministers over drug pricing and NHS adoption.
This friction were exacerbated by claims that American consumers were charged significantly more for the same drugs than people in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar investments have been announced toward American operations.
One official publicly accepted that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had declined as a share of its resources over the last ten years.
